Beam Therapeutics (BEAM) Notes Payables (2019 - 2026)

Beam Therapeutics (BEAM) has reported Notes Payables for 8 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Notes Payables changed 0.0% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (changed 0.0% YoY), while the FY2025 annual figure was $7.7 million, down 8.33% from the prior year.
• Notes Payables retreated to $5.2 million in Q1 2026 per BEAM's latest filing, from $7.7 million in the prior quarter.
• Across five years, Notes Payables topped out at $28.6 million in Q1 2022 and bottomed at $3.9 million in Q2 2025.
• Historically, Notes Payables has averaged $11.6 million across 5 years, with a median of $8.9 million in 2023.
• Annual changes were most pronounced in 2022 — Notes Payables tumbled 80.8% — and 2024, when it rose 7.87%.
• Beam Therapeutics' Notes Payables stood at $18.3 million in 2022, then sank by 40.98% to $10.8 million in 2023, then decreased by 22.22% to $8.4 million in 2024, then fell by 8.33% to $7.7 million in 2025, then plunged by 32.47% to $5.2 million in 2026.
• Business Quant data shows BEAM's Notes Payables at $5.2 million in Q1 2026, $7.7 million in Q4 2025, and $6.5 million in Q3 2025.